Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Thalidomide+Glutamine

Phase 2Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Injury

NCT06617182

Clinical

Trials by Indication[1]

Injury1 trial

Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.

Not yet recruiting·YYongquan Shi·Phase 2·NCT06617182·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Thalidomide+Glutamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thalidomide+Glutamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thalidomide+Glutamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yongquan Shi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: YYongquan Shi

Related News